AIM
KPTI icon

Aigen Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

Aigen Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,527
Closed -$728K – 1069
2020
Q1 		$728K Sell
2,527
-686
-21% -$189K 0.1% 302
2019
Q4 		$924K Buy
+3,213
New +$697K 0.15% 194

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Aigen Investment Management's KPTI Position: Q2 2020 in Review

Aigen Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 2,527 shares — an estimated $728K sold.

Aigen Investment Management first reported a position in KPTI in Q4 2019 and held it in 2 quarters. The position peaked at $924K in Q4 2019. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

  • Aigen Investment Management reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Aigen Investment Management sold 2,527 Karyopharm Therapeutics shares in Q2 2020, an estimated $728K.
  • Aigen Investment Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 2 quarters.
  • Aigen Investment Management's Karyopharm Therapeutics position peaked at $924K in Q4 2019.
  • 155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on Aigen Investment Management's 13F filing for Q2 2020, filed 10 Aug 2020.